Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ZR-202-CoV / Walvax
NCT04990544: Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19	Active, not recruiting	2	528	RoW	202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose, Placebo	Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd.	COVID-19	04/22	11/23
NCT05313022: Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19	Active, not recruiting	1/2	84	RoW	ZR-202-CoV, Placebo	Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd.	COVID-19	05/22	06/23
NCT05490108: Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.	Active, not recruiting	1/2	60	RoW	ZR202-CoV, ZR202a-CoV, Comirnaty®	Shanghai Zerun Biotechnology Co.,Ltd	SARS-CoV-2 Infection, COVID-19	09/22	08/23
NCT04982068: Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19	Active, not recruiting	1	72	RoW	202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose, Placebo	Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd.	COVID-19	10/21	06/23